Tolerability: Generally well tolerated based on existing research
Retatrutide is an investigational triple-hormone receptor agonist developed by Eli Lilly that targets three receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon
Cities We Cover We bring mobile IV therapy to homes, hotels, and offices across these communities
GIP receptor activation in adipose tissue influences lipid storage and mobilization, and in the brain, it contributes to appetite regulation through mechanisms that complement GLP-1 signaling
Pros: Extended half-life compared to unmodified MGF, in theory allowing fewer, more practical dosing intervals Mechanism aligns with well-studied endogenous muscle-repair biology (satellite cell activation, IGF-1 pathway) Widely available from research-chemical vendors for lab/research purposes Cons: No FDA approval, no completed human clinical trials, and no regulator-reviewed safety or efficacy data Prohibited in competitive sport under WADA growth-factor rules Product quality and purity vary significantly between unregulated research-chemical suppliers Side Effects: Not well characterized due to the absence of an approved label
